BRIC-Translational Health Science and Technology Institute (BRIC-THSTI), in collaboration with Miltenyi Biotec and the Biotechnology Industry Research Assistance Council (BIRAC), has announced the launch of India’s first hands-on training programme on the Foundations of Cell and Gene Therapy (CGT) Manufacturing, with a special focus on CAR-T cell therapy. This pioneering initiative is designed to bridge the gap between research and clinical application by equipping early-career scientists and clinicians with comprehensive, practical experience, spanning pre-clinical development, GMP-compliant manufacturing and clinical translation. The workshop titled “CAR-T Cell Therapy Manufacturing Hands-on Workshop and Symposia” has taken place at THSTI, NCR Biotech Science Cluster, from 12–14 November 2025.
Participants, including researchers, clinicians and industry professionals from across India will engage in an intensive three-day, experiential training, following access to Miltenyi University’s online curriculum. The workshop is designed to deliver end-to-end exposure to CGT manufacturing: from preclinical development, through closed-system cell processing, to rigorous quality-control and compliance practices. “Through this collaboration with THSTI and BIRAC, we are investing in India’s next-generation scientific talent to ensure that advanced therapies can be translated from bench to bedside in a way that is local, relevant and sustainable,” said Dr. Priya Kapoor G. Hingorani, Managing Director, Miltenyi Biotec India.
“Our partnership with Miltenyi Biotec and BIRAC marks a significant step forward in strengthening India’s translational research ecosystem.”,noted Prof. G. Karthikeyan, Executive Director, BRIC-THSTI. “BIRAC has been committed to nurturing India’s biotechnology ecosystem through innovation-driven public-private partnerships,” added Dr. Jitendra Kumar, Managing Director, BIRAC. This joint initiative by THSTI, Miltenyi Biotec and BIRAC underscores a shared vision to build local expertise, enhance translational capabilities and foster an enabling ecosystem for precision medicine in India.